Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-07 |
2024-03 |
0 |
-0.3 |
N/A |
N/A |
2024-03-25 |
2023-12 |
0 |
-0.32 |
N/A |
N/A |
2023-11-13 |
2023-09 |
0 |
-0.19 |
N/A |
N/A |
2023-08-08 |
2023-06 |
0 |
-0.34 |
N/A |
N/A |
2023-05-11 |
2023-03 |
0 |
-0.3 |
N/A |
N/A |
2023-03-30 |
2022-12 |
0 |
-0.36 |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2014-05-21 |
BALLANTYNE CHARLES EVAN |
Chief Financial Officer |
10.00K |
Purchase |
2014-04-29 |
KANZER STEVE H |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2019-04-02 |
KIRK RANDAL JOE |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2017-03-13 |
KRAWS JEFFREY J |
Director |
228.77K |
Conversion of Exercise of derivative security |
2011-08-29 |
KUO JAMES S |
Chief Executive Officer |
4.50K |
Purchase |
2009-12-06 |
LYON LYMAN MAX JR |
Chief Executive Officer |
45.00K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
525.37K |
525.37K |
3.08% |
2023-06-29 |
Blackrock Inc. |
190.17K |
190.17K |
1.12% |
2023-06-29 |
Geode Capital Management, LLC |
116.30K |
116.30K |
0.68% |
2023-06-29 |
State Street Corporation |
48.69K |
48.69K |
0.29% |
2023-06-29 |
Renaissance Technologies, LLC |
38.71K |
38.71K |
0.23% |
2023-06-29 |
Bridgeway Capital Management, Inc. |
28.53K |
28.53K |
0.17% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
330.87K |
330.87K |
1.94% |
2023-06-29 |
Vanguard Extended Market Index Fund |
194.49K |
194.49K |
1.14% |
2023-05-30 |
Fidelity Extended Market Index Fund |
66.72K |
46.04K |
0.39% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
28.53K |
28.53K |
0.17% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
14.86K |
10.25K |
0.09% |
2023-07-30 |
Schwab Capital Trust-Total Stock Market Index Fund |
13.57K |
9.09K |
0.08% |